Biotech closes on $9M for stem cell, cord blood research

09/14/2007 | American City Business Journals

Aldagen has raised $9 million in funding to use for its research with stem cells derived from bone marrow, blood and umbilical cords. The biotech company currently has three drugs trials under way for improving safety in cord blood transfusions and treating advanced heart failure and blocked extremities.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY